# Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

> **NCT05451043** · PHASE2 · RECRUITING · sponsor: **AHS Cancer Control Alberta** · enrollment: 62 (estimated)

## Conditions studied

- Pancreatic Cancer
- Hepatocellular Cancer
- Biliary Tract Cancer
- Cholangiocarcinoma

## Interventions

- **BIOLOGICAL:** Durvalumab
- **DRUG:** Gemcitabine
- **DRUG:** Nab paclitaxel
- **BIOLOGICAL:** Tremelimumab
- **DRUG:** Propranolol
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT05451043
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-05
- **Primary completion:** 2026-10-01
- **Final completion:** 2029-10-01
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05451043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05451043, "Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05451043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*